Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.64 is in line with its 5-year average of -0.65, around the middle of its 5-year range (-1.03–-0.19).
5.79% below its 12-month average of -0.60.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.19.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 39 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:56:11.906Z. Historical observations retain their original dates. Historical series through 2022-03-10.
EARNINGS PER SHARE (EPS)
-0.64
EARNINGS PER SHARE (EPS) AVG TTM
-0.60
EARNINGS PER SHARE (EPS) AVG 3Y
-0.67
EARNINGS PER SHARE (EPS) AVG 5Y
-0.65
EARNINGS PER SHARE (EPS) AVG 10Y
-1.25
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.79%
CURRENT VS 3Y AVG
+3.86%
CURRENT VS 5Y AVG
+1.36%
CURRENT VS 10Y AVG
+48.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Corvus Pharmaceuticals, Inc.
Market Cap
$866.51M
Earnings Per Share (EPS)
-0.64
TTM Avg
-0.60
3Y Avg
-0.67
5Y Avg
-0.65
Market Cap
$860.37M
Earnings Per Share (EPS)
16.32
TTM Avg
10.69
3Y Avg
4.14
5Y Avg
2.27
Market Cap
$860.28M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.59
3Y Avg
-1.03
5Y Avg
-1.22
Market Cap
$878.06M
Earnings Per Share (EPS)
0.78
TTM Avg
-0.28
3Y Avg
-0.36
5Y Avg
-0.51
Market Cap
$855.16M
Earnings Per Share (EPS)
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$849.66M
Earnings Per Share (EPS)
-15.44
TTM Avg
-23.62
3Y Avg
-9.43
5Y Avg
-0.29
Market Cap
$844.84M
Earnings Per Share (EPS)
-0.43
TTM Avg
-1.48
3Y Avg
-1.39
5Y Avg
-1.04
Market Cap
$840.85M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.25
3Y Avg
-1.25
5Y Avg
-1.25
Market Cap
$837.03M
Earnings Per Share (EPS)
-1.68
TTM Avg
-1.54
3Y Avg
-1.41
5Y Avg
-1.41
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $866.51M | -0.64 | -0.60 | -0.67 | -0.65 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.37M | 16.32 | 10.69 | 4.14 | 2.27 |
| SI-BONE, Inc. (SIBN)vs › | $860.28M | -0.34 | -0.59 | -1.03 | -1.22 |
| Arbutus Biopharma Corp (ABUS)vs › | $878.06M | 0.78 | -0.28 | -0.36 | -0.51 |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | N/A | 0.00 | 0.00 | 0.00 |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | -15.44 | -23.62 | -9.43 | -0.29 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | -0.43 | -1.48 | -1.39 | -1.04 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.85M | N/A | -1.25 | -1.25 | -1.25 |
| Beta Bionics, Inc. (BBNX)vs › | $837.03M | -1.68 | -1.54 | -1.41 | -1.41 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.98M | -2.18 | -0.78 | -1.63 | -1.49 |
Trailing EPS (TTM)
$-0.64
Forward EPS (Est.)
$-0.75
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.19 |
| 2024-12-31 | -1.02 |
| 2023-12-31 | -0.56 |
| 2022-12-31 | -0.89 |
| 2021-12-31 | -1.03 |
| 2020-12-31 | -0.20 |
| 2019-12-31 | -1.49 |
| 2018-12-31 | -1.71 |
| 2017-12-31 | -2.72 |
| 2016-12-31 | -2.36 |
| 2015-12-31 | -1.54 |
| 2014-12-31 | -1.03 |
